On November 14, 2022, Bruker Corporation, a Nasdaq-listed provider of scientific instruments and analytical and diagnostic solutions, acquired Neurescence Inc., an innovative provider of ultra-light fiber-bundle multiscopes for simultaneous multi-region, optical functional neuroimaging. Neurescence’s flagship product Chromatone moves illumination and detection hardware off the animal head. This enables simultaneous imaging and stimulation of three sub-types of neurons in four regions for flexible investigation of the central nervous system with single-neuron resolution in naturalistic behavior. This platform creates strong synergies with Bruker’s existing Ultima multiphoton solutions and newly acquired Inscopix head-mounted miniscopes.
Davies Ward Phillips & Vineberg LLP acted as counsel to Bruker, with a team that included Michel Gélinas, Ryan Brun and Michelle Vesely (M&A/Life Sciences); Olivia Khazam (Tax); Gillian Stacey and Benoit Archambault (Technology/IP); and Shari Cohen (Employment).
Torys LLP acted as counsel to Neurescence Inc. with a team led by Jordan Wright.
